... is a risk of developing HIV resistance if SUSTIVA is underdosed. Bristol-Myers Squibb remains at the forefront of HIV/AIDS research and continues to pursue the development of treatment options for children and adults with HIV. Studies are ongoing ...
http://eon.businesswire.com/news/eon/20130503005314/en/Bristol-Myers-Squibb-Receives-FDA-sNDA-Approval-SUSTIVA%C2%AE
http://eon.businesswire.com/news/eon/20130503005314/en/Bristol-Myers-Squibb-Receives-FDA-sNDA-Approval-SUSTIVA%C2%AE
No comments:
Post a Comment